Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

55.50 -4.73 (-7.85%)
Streaming Delayed Price Updated: 11:44 AM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish
CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 
Via Stocktwits
Topics Government
Exposures Political Product Safety
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
Via Benzinga
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks. 
Via Benzinga
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
Company to host conference call on April 7 at 8 a.m. ET 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts
Via Benzinga
What's Next: Rhythm Pharmaceuticals's Earnings Preview
Via Benzinga
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
New registry study to focus on impact of fatigue in people with craniopharyngioma 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion 
Via Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.